Vanda Pharmaceuticals Up, Nike Gains, Biggest Winners of 2025

On this episode of Stock Movers:
- Vanda Pharmaceuticals (VNDA) shares soar as much as 24% in premarket trading on Wednesday after the biopharmaceutical company said the US FDA has approved Nereus (tradipitant) for the prevention of vomiting induced by motion.
- Nike (NKE) shares rose 1.6% in postmarket trading after CEO Elliott Hill reported the purchase of about $1 million in shares.
- The S&P 500 Index is poised to end 2025 up more than 17% as the bull market continues for a third year driven by enthusiasm for artificial intelligence. The AI trade broadened out this year, as chip stocks again led the S&P 500 but were joined by the shares of companies tied to building the data centers that will power the technology. Three of the index’s top 10 performers in 2025 were data storage companies, which are among the main beneficiaries of the hundreds of billions of dollars in pledged spending by the giant AI cloud service providers known as hyperscalers. On the flip side, economic uncertainty from President Donald Trump’s sweeping tariffs weighed on the shares of consumer companies, while health-care stocks struggled with uncertainty surrounding the administration’s policies and pressure on drug prices. 

See omnystudio.com/listener for privacy information.